marketreportdesk

 Pfizer announced the co-primary endpoint results of the ORAL Surveillance (NCT02092467) post-marketing safety study of Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor, in RA patients with cardiovascular (CV) risk factors. According to the findings of the study, Xeljanz failed to demonstrate non-inferiority to treatment with a tumor necrosis factor inhibitor in terms of the risk of major adverse cardiovascular events (MACE) and cancer (excluding non-melanoma skin cancer) at doses of 5 mg and 10 mg twice daily, respectively. These results suggest that Xeljanz and possibly other JAK inhibitor products will face difficulties in the future. Janus Kinase Drugs Development market Surveillance trial in the middle of the study in early 2019 because of links between the 10 mg twice daily dose of Xeljanz and a higher risk of thrombosis and overall mortality. Despite the fact that there were no safety warnings for the 5mg twice-daily dose at the time, some important opinion leaders who...

Chris Ricciardi has been appointed managing partner and head of business development at GrizzlyRock Capital, an alternative asset management firm that focuses on the credit and equity markets, and Doug Laux has been appointed chief financial officer. According to Saidal Mohmand, the company's vice president of investment research, Ricciardi and Laux will collaborate with Kyle Mowery, who established GrizzlyRock in 2012. Ricciardi was responsible for distributing private and public investment solutions to professional investors, wealth managers, banks, and financial services platforms at Altegris Investments before joining GrizzlyRock as director of strategic relationships. Furthermore, he was also a co-founder of Herron Capital Management. Laux worked for Ernst & Young in Chicago for 20 years, where he was a partner for nine years. Prior to this, he also held the position of chief financial officer for a number of businesses, including Alamo and National Car Rental Market hold...